Survival Trends in Metastatic Renal Cell Carcinoma Across Therapeutic Eras and Histologic Subtypes
Sai Tharun Reddy Gopannagari, Ganisetti Divya, Kesava Manikanta Achuta, Chadi Saad · 2026
Read Survival Trends in Metastatic Renal Cell Carcinoma Across Therapeutic Eras and Histologic Subtypes by Sai Tharun Reddy Gopannagari, Ganisetti Divya, Kesava Manikanta Achuta, Chadi Saad (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13222081.txt.
Description
Sai Gopannagari and co-authors track in 2026 whether newer drugs have lengthened life in spread kidney cancer. Using a national cancer registry, they compared 7,356 patients diagnosed in the targeted-drug era, 2006 to 2015, with those in the immune therapy era, 2016 to 2022.
Median survival rose from 13 to 17 months across the eras, and cancer-specific survival rose too. Later diagnosis carried about a fifth lower risk of death after other factors were counted. The gain came mostly from the clear cell subtype, the most common form. Papillary and chromophobe subtypes gained less and less surely. The authors call for subtype-specific strategies for the rarer forms.
Catalog record
| CREATOR | Sai Tharun Reddy Gopannagari, Ganisetti Divya, Kesava Manikanta Achuta, Chadi Saad |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |